VANDA PHARMACEUTICALS INC. (VNDA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 164.03M USD | Liabilities, Current |
| Cash and equivalents | 55.88M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 59.69M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.68M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $164.03M | $55.88M | (m) | $59.69M | $1.68M | (m) |
| 2026-03-31 | (m) | $135.58M | $54.03M | (m) | $56.88M | $1.70M | (m) |
| 2025-12-31 | (m) | $145.16M | $84.85M | (m) | $54.58M | $1.85M | (m) |
| 2025-09-30 | (m) | $117.87M | $70.02M | (m) | $50.54M | $2.04M | (m) |
| 2025-06-30 | (m) | $121.49M | $80.98M | (m) | $44.99M | $2.17M | (m) |
| 2025-03-31 | (m) | $103.92M | $111.80M | (m) | $44.60M | $1.92M | (m) |
| 2024-12-31 | (m) | $99.98M | $102.32M | (m) | $47.10M | $1.73M | (m) |
| 2024-09-30 | (m) | $89.09M | $100.50M | (m) | $42.75M | $1.61M | (m) |
| 2024-06-30 | (m) | $93.79M | $102.95M | (m) | $41.86M | $1.47M | (m) |
| 2024-03-31 | (m) | $93.34M | $125.16M | (m) | $36.71M | $1.50M | (m) |
| 2023-12-31 | (m) | $87.70M | $135.82M | (m) | $34.16M | $1.36M | (m) |
| 2023-09-30 | (m) | $84.84M | $183.19M | (m) | $29.27M | $1.01M | (m) |
| 2023-06-30 | (m) | $87.40M | $150.03M | (m) | $33.62M | $1.08M | (m) |
| 2023-03-31 | (m) | $93.79M | $354.17M | (m) | $24.51M | $1.10M | (m) |
| 2022-12-31 | (m) | $91.44M | $135.03M | (m) | $33.51M | $1.19M | (m) |
| 2022-09-30 | (m) | $92.62M | $49.40M | (m) | $29.35M | $1.59M | (m) |
| 2022-06-30 | $469.66M | $88.40M | $58.23M | $382.63M | $28.80M | $1.50M | 5.31× |
| 2022-03-31 | $465.67M | $90.74M | $66.93M | $368.25M | $30.50M | $1.29M | 5.13× |
| 2021-12-31 | $465.28M | $74.42M | $52.07M | $380.74M | $32.47M | $1.02M | 6.25× |
| 2021-09-30 | $447.46M | $72.00M | $50.52M | $355.45M | $41.50M | $902.00K | 6.22× |
| 2021-06-30 | $433.58M | $71.99M | $57.24M | $339.25M | $37.09M | $1.05M | 6.02× |
| 2021-03-31 | $409.64M | $61.78M | $72.13M | $306.03M | $31.47M | $1.36M | 6.63× |
| 2020-12-31 | $397.78M | $65.94M | $61.03M | $306.71M | $30.04M | $1.28M | 6.03× |
| 2020-09-30 | $376.58M | $61.36M | $56.97M | $291.57M | $28.03M | $1.32M | 6.14× |
| 2020-06-30 | $364.44M | $61.59M | $95.31M | $244.54M | $24.59M | $1.38M | 5.92× |
| 2020-03-31 | $341.60M | $59.22M | $64.95M | $247.38M | $29.27M | $1.32M | 5.77× |
| 2019-12-31 | $338.50M | $59.51M | $45.07M | $267.06M | $26.37M | $1.14M | 5.69× |
| 2019-09-30 | $264.61M | $60.00M | $39.21M | $198.58M | $26.82M | $1.02M | 4.41× |
| 2019-06-30 | $304.05M | $62.58M | $46.54M | $233.62M | $23.89M | $1.06M | 4.86× |
| 2019-03-31 | $294.18M | $59.27M | $34.38M | $233.46M | $26.35M | $1.11M | 4.96× |
| 2018-12-31 | $286.14M | $53.02M | $61.01M | $196.35M | $28.78M | $994.00K | 5.40× |
| 2018-09-30 | $265.84M | $46.24M | $60.78M | $179.80M | $25.26M | $887.00K | 5.75× |
| 2018-06-30 | $256.07M | $46.88M | $60.89M | $170.32M | $24.86M | $1.19M | 5.46× |
| 2018-03-31 | $272.15M | $71.95M | $155.29M | $93.54M | $23.31M | $1.01M | 3.78× |
| 2017-12-31 | $161.01M | $70.36M | $33.63M | $109.79M | $17.60M | $840.00K | 2.29× |
| 2017-09-30 | $158.06M | $71.54M | $22.59M | $117.30M | $18.18M | $921.00K | 2.21× |
| 2017-06-30 | $158.14M | $75.44M | $14.23M | $122.89M | $21.02M | $742.00K | 2.10× |
| 2017-03-31 | $155.51M | $72.97M | $20.11M | $117.64M | $17.75M | $816.00K | 2.13× |
| 2016-12-31 | $161.61M | $50.32M | $40.43M | $100.91M | $20.27M | $779.00K | 3.21× |
| 2016-09-30 | $158.51M | $50.68M | $32.77M | $109.81M | $15.93M | $865.00K | 3.13× |
| 2016-06-30 | $150.02M | $51.76M | $23.19M | $112.80M | $14.03M | $927.00K | 2.90× |
| 2016-03-31 | $155.01M | $55.04M | $38.74M | $99.59M | $16.68M | $938.00K | 2.82× |
| 2015-12-31 | $159.51M | $51.32M | $50.84M | $92.34M | $16.33M | $1.29M | 3.11× |
| 2015-09-30 | $160.10M | $45.89M | $46.79M | $97.53M | $15.79M | $3.80M | 3.49× |
| 2015-06-30 | $162.46M | $45.19M | $48.34M | $98.30M | $15.82M | $4.96M | 3.59× |
| 2015-03-31 | $154.45M | $31.79M | $32.81M | $101.52M | $20.12M | $5.21M | 4.86× |
| 2014-12-31 | $133.48M | $7.79M | $60.90M | $68.92M | $3.65M | $5.17M | 17.14× |
| 2014-09-30 | $59.78M | $38.84M | $15.31M | $40.78M | $3.70M | $1.27M | 1.54× |
| 2014-06-30 | $65.96M | $38.29M | $16.99M | $46.59M | $2.38M | $1.09M | 1.72× |
| 2014-03-31 | $102.09M | $45.40M | $43.26M | $57.14M | $1.69M | $192.00K | 2.25× |
| 2013-12-31 | $132.38M | $32.85M | $64.76M | $65.59M | $2.03M | (m) | 4.03× |
| 2013-09-30 | (m) | $31.91M | $142.17M | (m) | $1.96M | (m) | (m) |
| 2013-06-30 | (m) | $31.93M | $103.63M | (m) | $1.64M | $28.00K | (m) |
| 2013-03-31 | $112.39M | $31.97M | $109.93M | $1.00M | $1.46M | $21.00K | 3.52× |
| 2012-12-31 | $121.57M | $32.26M | $88.77M | $31.63M | $1.17M | $57.00K | 3.77× |
| 2012-09-30 | $135.94M | $34.63M | $104.52M | $29.89M | $1.53M | $161.00K | 3.93× |
| 2012-06-30 | $146.40M | $34.39M | $94.39M | $50.31M | $1.70M | $165.00K | 4.26× |
| 2012-03-31 | $158.78M | $32.66M | $108.09M | $49.16M | $1.53M | (m) | 4.86× |
| 2011-12-31 | $150.50M | $31.62M | $87.92M | $60.96M | $1.62M | (m) | 4.76× |
| 2011-09-30 | $162.66M | $33.64M | $60.33M | $101.12M | $1.22M | (m) | 4.84× |
| 2011-06-30 | $189.15M | $32.86M | $50.39M | $138.01M | $752.00K | (m) | 5.76× |
| 2011-03-31 | (m) | (m) | $52.52M | (m) | (m) | (m) | (m) |
| 2010-12-31 | $198.55M | $31.03M | $42.56M | $155.48M | $511.00K | (m) | 6.40× |
| 2010-09-30 | (m) | (m) | $102.47M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $145.65M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $205.29M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $39.08M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |